Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamel Laribi

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Blood Advances|October 7, 2020
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patientsKamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
European Journal of Haematology|May 3, 2018
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overloadChristian Rose, Caroline Lenoir, Emmanuel Gyan, et al.
Haematologica|February 9, 2018
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE studyAnne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma|February 11, 2020
Lymphomas with kidney involvement: the French multicenter retrospective LyKID studyMilena Kohn, Alexandre Karras, Mohamad Zaidan, et al.
British Journal of Clinical Pharmacology|January 9, 2020
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in VigibaseJustine Perino, Nathan Mottal, Yohann Bohbot, et al.
Ejhaem|February 23, 2023
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in EuropeMark J Bishton, Gilles Salles, Camille Golfier, et al.
Haematologica|April 23, 2026
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experienceGaetan Basile, Arnaud Neuville, Delphine Martineau, et al.
Acta Oncologica (Stockholm, Sweden)|August 4, 2021
Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literatureMagdalena Olszewska-Szopa, Marta Sobas, Kamel Laribi, et al.
British Journal of Haematology|May 23, 2013
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS studyEmmanuel Gyan, Diane Damotte, Stéphane Courby, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Blood Advances|October 7, 2020
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patientsKamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
European Journal of Haematology|May 3, 2018
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overloadChristian Rose, Caroline Lenoir, Emmanuel Gyan, et al.
Haematologica|February 9, 2018
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE studyAnne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma|February 11, 2020
Lymphomas with kidney involvement: the French multicenter retrospective LyKID studyMilena Kohn, Alexandre Karras, Mohamad Zaidan, et al.
British Journal of Clinical Pharmacology|January 9, 2020
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in VigibaseJustine Perino, Nathan Mottal, Yohann Bohbot, et al.
Ejhaem|February 23, 2023
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in EuropeMark J Bishton, Gilles Salles, Camille Golfier, et al.
Haematologica|April 23, 2026
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experienceGaetan Basile, Arnaud Neuville, Delphine Martineau, et al.
Acta Oncologica (Stockholm, Sweden)|August 4, 2021
Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literatureMagdalena Olszewska-Szopa, Marta Sobas, Kamel Laribi, et al.
British Journal of Haematology|May 23, 2013
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS studyEmmanuel Gyan, Diane Damotte, Stéphane Courby, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Pageof 11